Articoli di riviste: "Cancérologie digestive"

1

BADER, J. P. "Pourquoi individualiser la cancérologie digestive ?" Cancéro digest, n. 1 (2009): 48. http://dx.doi.org/10.4267/2042/25069.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Rey, Jean-François. "Cancérologie digestive : L’Importance des UCPO". Acta Endoscopica 34, n. 2 (aprile 2004): 260–61. http://dx.doi.org/10.1007/bf03009020.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Étienne, Jacques, Philippe Ducrotté, Jean-Marc Canard e Jean-Christophe Létard. "La photothérapie dynamique en cancérologie digestive". Hegel N° 1, n. 1 (2011): 20. http://dx.doi.org/10.4267/2042/38778.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Étienne, Jacques, Philippe Ducrotté, Jean-Marc Canard e Jean-Christophe Létard. "La photothérapie dynamique en cancérologie digestive". Hegel N° 1, n. 1 (1 gennaio 2011): 20–25. http://dx.doi.org/10.3917/heg.011.0020.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Lledo, G., e P. Artru. "La cancérologie digestive à l’ASCO 2000". Acta Endoscopica 30, S1 (settembre 2000): 278–82. http://dx.doi.org/10.1007/bf03021871.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Mitry, E. "La consultation d’annonce en cancérologie digestive". Côlon & Rectum 1, n. 4 (novembre 2007): 272–75. http://dx.doi.org/10.1007/s11725-007-0054-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Estable, P. "III.5 Nouveautés en cancérologie digestive". Acta Endoscopica 21, S1 (gennaio 1991): 137–39. http://dx.doi.org/10.1007/bf02970838.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Rebischung, C., e M. Laramas. "Les traitements néo-adjuvants en cancérologie digestive". Journal de Chirurgie 144, n. 5 (ottobre 2007): 393–97. http://dx.doi.org/10.1016/s0021-7697(07)73993-5.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Boutayeb, S., Y. Bensouda, Z. Fadoulkhair, K. Bakkraoui, M. Bachouchi e H. Errihani. "Les thérapies ciblées dans la cancérologie digestive". Pathologie Biologie 60, n. 4 (agosto 2012): 264–68. http://dx.doi.org/10.1016/j.patbio.2012.05.013.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Lecomte, T., e E. Vaillant. "Actualités en cancérologie digestive à l’UEGW 2016". Acta Endoscopica 47, n. 1 (19 gennaio 2017): 36–38. http://dx.doi.org/10.1007/s10190-017-0582-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

11

Montravers, F., e J. N. Talbot. "Tomographie par émission de positons en cancérologie digestive". EMC - Radiologie et imagerie médicale - Abdominale - Digestive 7, n. 2 (giugno 2012): 1–14. http://dx.doi.org/10.1016/s1879-8527(12)55045-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

Azaloux, H., M. A. Chanol, P. Escarmant, S. Gromb, P. Cart-Lami e A. Moris. "Cancérologie digestive en Martinique et marqueurs tumoraux plasmatiques". Trait - d'Union 2, n. 2 (giugno 1987): 42–44. http://dx.doi.org/10.1016/s0980-9090(87)80029-0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Bazine, A., M. Fetohi, E. Choukri, K. A. Slimani, M. Ichou e H. Errihani. "Toxicité cutanée des thérapies ciblées en cancérologie digestive". Journal Africain d'Hépato-Gastroentérologie 8, n. 4 (22 agosto 2014): 212–16. http://dx.doi.org/10.1007/s12157-014-0562-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Rougier, P., P. Pienkovski e P. Michel. "Les hépatogastroentérologues et la chimiothérapie en cancérologie digestive". Côlon & Rectum 4, n. 4 (novembre 2010): 241–42. http://dx.doi.org/10.1007/s11725-010-0257-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Bretagne, Jean-François, e Sylvain Manfredi. "Quel est le rôle de l’hépato-gastroentérologue en cancérologie digestive ?" Gastroentérologie Clinique et Biologique 30, n. 11 (novembre 2006): 1241–43. http://dx.doi.org/10.1016/s0399-8320(06)73531-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Coulom, Pierre, e Patrice Pienkowski. "Premier Symposium Cregg De Cancérologie Digestive Libérale Aux JFPD 2008". Acta Endoscopica 38, n. 2 (giugno 2008): 193. http://dx.doi.org/10.1007/bf02961958.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Legoux, Jean-Louis, Laurent Bedenne, Jean-François Seitz, Denis Pezet, Philippe Rougier, Olivier Bouché, Jean-Claude Barbare et al. "Quels changements dans le Thésaurus National de Cancérologie Digestive en 2005 ?" Gastroentérologie Clinique et Biologique 30, n. 10 (ottobre 2006): 1191–95. http://dx.doi.org/10.1016/s0399-8320(06)73510-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Montravers, Franc¸oise, Eric Zerbib, Dany Grahek, Khaldoun Kerrou, Nassima Younsi e Jean-Noël Talbot. "Tomographie par émission de positons au [18F]-fluorodésoxyglucose en cancérologie digestive". EMC - Radiologie et imagerie médicale - Abdominale - Digestive 1, n. 1 (gennaio 2006): 1–10. http://dx.doi.org/10.1016/s1879-8527(06)74699-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Alves, Arnaud, e Olivier Dejardin. "Comment étudier l’influence des inégalités sociales de santé en cancérologie digestive ?" Hépato-Gastro & Oncologie Digestive 30, n. 7 (settembre 2023): 657–60. http://dx.doi.org/10.1684/hpg.2023.2619.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Bouché, O., E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-Benmansour e S. Lagarde. "Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires". Gastroentérologie Clinique et Biologique 33, n. 4 (aprile 2009): 306–22. http://dx.doi.org/10.1016/j.gcb.2009.02.008.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Methy, N., L. Bedenne e F. Bonnetain. "Critères de substitution: méthodes de validation et état des lieux en cancérologie digestive". Bulletin du Cancer 96, n. 5 (maggio 2009): 591–95. http://dx.doi.org/10.1684/bdc.2009.0858.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Rialland, F., F. Méchinaud, H. Piloquet, M. F. De La Cochetière e D. Darmaun. "SFCE-P16 – Cancérologie – Etat nutritionnel et marqueurs d’inflammation digestive après greffe de moelle". Archives de Pédiatrie 15, n. 5 (giugno 2008): 1011. http://dx.doi.org/10.1016/s0929-693x(08)72358-3.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Guigou, David. "Les douleurs en cancérologie digestive : regarder au-delà pour réussir à les traiter". Gastroentérologie Clinique et Biologique 28, n. 5 (maggio 2004): 11–16. http://dx.doi.org/10.1016/s0399-8320(04)94982-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Bouché, Olivier. "Les biothérapies ciblées en cancérologie digestive : une nouvelle ère dans la stratégie thérapeutique ?" Gastroentérologie Clinique et Biologique 29, n. 5 (maggio 2005): 495–500. http://dx.doi.org/10.1016/s0399-8320(05)82118-9.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

LLEDO, Gérard, e Pascal ARTRU. "Un nouveau Cancéro digest pour ne rien rater de l’actualité en cancérologie digestive…". Cancéro digest, n. 1 (2009): 1. http://dx.doi.org/10.4267/2042/25060.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Culine, S., J. Gligorov, I. Krakowski, P. Marti, J.-P. Metges, D. Serin, M. Schneider e M. Spielmann. "Une première collaboration entre Oncologie et la Fédération Française de Cancérologie Digestive (FFCD) !" Oncologie 16, n. 11-12 (dicembre 2014): 483. http://dx.doi.org/10.1007/s10269-014-2476-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Rouillon, J. M., e P. Pienkowski. "Quelle place pour les hépato-gastro-entérologues dans l’exercice de la cancérologie digestive?" Acta Endoscopica 38, S1 (marzo 2008): S30—S33. http://dx.doi.org/10.1007/s101900800029.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Campedel, L., S. Assoun, S. Bécourt, O. Nguyen, F. Ledoux, L. Doucet, M. Espié e L. Teixeira. "Toxicités sévères des immunothérapies du cancer". Médecine Intensive Réanimation 27, n. 6 (novembre 2018): 522–36. http://dx.doi.org/10.3166/rea-2018-0070.

Testo completo

Abstract (sommario):

L’immunothérapie représente une avancée récente et importante en cancérologie. Les inhibiteurs de checkpoints immunitaires, ciblant les protéines PD-1, PD-L1 et CTLA-4, sont les thérapies les plus prometteuses et sont utilisés dans la prise en charge de plusieurs cancers. Les toxicités associées à ces traitements sont généralement moins fréquentes et moins graves que celles associées aux chimiothérapies et à la plupart des thérapies ciblées. Cependant, il existe un certain nombre de toxicités spécifiques de ce type de traitement, qui peuvent parfois être sévères et dont les plus fréquentes sont les toxicités pulmonaire, digestive, endocrinienne et cutanée. Dans cette mise au point, nous reviendrons sur la fréquence, le mécanisme et les principes de traitement des différentes toxicités sévères associées à l’immunothérapie.

Gli stili APA, Harvard, Vancouver, ISO e altri

29

Metges, J. P., A. Volant, F. Grudé, O. Pradier, C. Riche, E. Gamelin e L. Corcos. "La recherche clinique en cancérologie digestive: de la cible à la véritable personnalisation du traitement?" Oncologie 11, n. 6 (giugno 2009): 325–30. http://dx.doi.org/10.1007/s10269-009-1079-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

Lledo, G. "Modalités d’exercice de la cancérologie digestive par un hépato-gastro-entérologue (HGE) en secteur libéral". Acta Endoscopica 33, S3 (giugno 2003): 462–63. http://dx.doi.org/10.1007/bf03002389.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Debrix, I., M. Sitbon, A. Khalil, A. Benomar, A. Becker e T. André. "Référentiel de bon usage et Thésaurus national de cancérologie digestive : analyse des écarts à l’hôpital Tenon". Bulletin du Cancer 96, n. 2 (febbraio 2009): 147–55. http://dx.doi.org/10.1684/bdc.2008.0820.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Methy, N., F. Bonnetain e L. Bedenne. "Critères de substitution de la survie globale dans les essais cliniques de cancérologie digestive : quels candidats ?" Revue d'Épidémiologie et de Santé Publique 56, n. 2 (maggio 2008): 87–88. http://dx.doi.org/10.1016/j.respe.2008.03.008.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Malka, David, Olivier Chapet, Laurence Chiche, Thierry De Baere, Clarisse Dromain, Frédéric Prat, Jean-Robert Delpero e Olivier Rosmorduc. "Cancer des voies biliaires : les tables de la loi. Les recommandations du Thésaurus National de Cancérologie Digestive". Cancéro digest 1, n. 2 (2009): 112. http://dx.doi.org/10.4267/2042/28036.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Legoux, J. L., P. Michel, P. Pienkowski, R. Faroux, B. Napoléon, T. Ponchon, O. Rosmorduc et al. "CO.87 Pratique de la cancérologie digestive par les hépato-gastroentérologues (HGE) : enquête nationale de la FSMAD". Gastroentérologie Clinique et Biologique 33, n. 3 (marzo 2009): A144. http://dx.doi.org/10.1016/s0399-8320(09)72883-0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

35

Legoux, J. L., P. Pienkowski, B. Napoléon, G. Lledo, C. Lecaille, F. Ricard e P. Rougier. "P.235 Pratique de la cancérologie digestive par les hépato-gastroentérologues libéraux : enquête nationale 2008 FSMAD-FFCD". Gastroentérologie Clinique et Biologique 33, n. 3 (marzo 2009): A166. http://dx.doi.org/10.1016/s0399-8320(09)72926-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

Dargent, F. "Particularités de la cancérologie animale Etude rétrospective de 50 cas de pathologie tumorale digestive spontanée du chien". Acta Endoscopica 29, n. 5 (ottobre 1999): 585–91. http://dx.doi.org/10.1007/bf03022173.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

May., Mabro. "Congrès annuel de l'American Society of Clinical Oncology, Orlando, Floride, mai 2002. L'actualité en cancérologie mammaire et digestive". La Revue de Médecine Interne 23, n. 12 (dicembre 2002): 957–59. http://dx.doi.org/10.1016/s0248-8663(02)00744-0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Lepage, C., A. M. Bouvier, G. Launoy e J. Faivre. "D1-4 - Évaluation du résultat des thérapeutiques lourdes en cancérologie digestive chez les patients de 80 ans et plus". Revue d'Épidémiologie et de Santé Publique 54 (agosto 2006): 37. http://dx.doi.org/10.1016/s0398-7620(06)76837-7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

39

Legoux, J. L., R. Faroux, P. Rougier, J. Butel, F. Ricard e H. Hagège. "P.234 Pratique de la cancérologie digestive par les hépato-gastroentérologues des Hôpitaux Généraux : enquête nationale 2008 FSMAD-FFCD". Gastroentérologie Clinique et Biologique 33, n. 3 (marzo 2009): A165. http://dx.doi.org/10.1016/s0399-8320(09)72925-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

40

Crehange, Gilles, Philippe Maingon, Karine Peignaux, Tan Dat N′guyen, Xavier Mirabel, Christian Marchal, Pierre Verrelle, Bernard Roullet, Franck Bonnetain e Laurent Bedenne. "Phase III Trial of Protracted Compared With Split-Course Chemoradiation for Esophageal Carcinoma: Fédération Francophone de Cancérologie Digestive 9102". Journal of Clinical Oncology 25, n. 31 (1 novembre 2007): 4895–901. http://dx.doi.org/10.1200/jco.2007.12.3471.

Testo completo

Abstract (sommario):

Purpose Chemoradiotherapy (CRT) is an alternative to surgery for resectable locally advanced esophageal carcinoma (RLA-EC). We investigated the heterogeneity of the treatment benefits across subgroups of patients, defined according to the radiation scheme. Patients and Methods Between February 1993 and December 2000, 451 patients were enrolled. The following two schemes were allowed: protracted radiotherapy (P-RT), which scheduled 46 Gy over 4.5 weeks or split-course radiotherapy (SC-RT) with two 1-week courses of 15 Gy. Two courses of cisplatin and fluorouracil were delivered concomitantly. In case of exclusive CRT, a further course of 20 Gy over 2 weeks in the P-RT group and one 1-week course of 15 Gy in the SC-RT group were delivered with three courses of chemotherapy. SC-RT and P-RT were administered to 285 patients (64%) and 161 patients (36%), respectively. Results For P-RT versus SC-RT, the response rate to induction CRT was 67% v 68%, respectively (P = .09), and 2-year local relapse-free survival rate was 76.7% v 56.8%, respectively (P = .002). Shorter tumor length and P-RT were associated with better local control in multivariate analysis (P = .002 for both). After a median follow-up time of 47.4 months, 2-year overall survival rate was 37.1% for P-RT compared with 30.5% for SC-RT (P = .25). Independent prognostic factors on survival were tumor diameter (P = .02), weight loss of 10% or less (P = .05), and response to induction CRT (P = .002). Conclusion Patients with RLA-EC treated with P-RT had better local control than patients treated with SC-RT. Response to induction CRT is a determinant prognostic factor on survival.

Gli stili APA, Harvard, Vancouver, ISO e altri

41

Michel, P., J. L. Legoux, T. Ponchon, O. Rosmorduc, G. Cadiot, F. Ricard e P. Rougier. "P.233 Pratique de la cancérologie digestive par les hépato-gastroentérologues des Centres Hospitalo-Universitaires : enquête nationale 2008 FSMAD-FFCD". Gastroentérologie Clinique et Biologique 33, n. 3 (marzo 2009): A165. http://dx.doi.org/10.1016/s0399-8320(09)72924-0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

42

Phelip, Jean-Marc, Véronique Vendrely, Florian Rostain, Fabien Subtil, Jean-Louis Jouve, Mohamed Gasmi, Pierre Michel et al. "Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study". European Journal of Cancer 50, n. 17 (novembre 2014): 2975–82. http://dx.doi.org/10.1016/j.ejca.2014.08.013.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Piessen, G. "Quel est le rôle de la chirurgie en cas de réponse clinique complète après chimio(radio)thérapie première en cancérologie digestive ?" Journal de Chirurgie Viscérale 151, n. 6 (dicembre 2014): 435–37. http://dx.doi.org/10.1016/j.jchirv.2014.07.010.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

44

Bedenne, L., AL Villing e B. Chauffert. "Lutte contre le cancer du pancréas exocrine: stagnation ou progrès ? Le point de vue de la Fondation française de cancérologie digestive (FFCD)". Cancer/Radiothérapie 1, n. 5 (novembre 1997): 555–63. http://dx.doi.org/10.1016/s1278-3218(97)89638-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

45

Michel, Pierre, Gilles Breysacher, Françoise Mornex, Jean François Seitz, Denis Pere-Verge, Isabelle Martel-Lafay, Roger Faroux et al. "Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308". European Journal of Cancer 50, n. 6 (aprile 2014): 1076–83. http://dx.doi.org/10.1016/j.ejca.2013.12.009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

46

Renfro, Lindsay A., Richard M. Goldberg, Axel Grothey, Alberto Sobrero, Richard Adams, Matthew T. Seymour, Volker Heinemann et al. "Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database". Journal of Clinical Oncology 35, n. 17 (10 giugno 2017): 1929–37. http://dx.doi.org/10.1200/jco.2016.71.5771.

Testo completo

Abstract (sommario):

Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.

Gli stili APA, Harvard, Vancouver, ISO e altri

47

Bedenne, L., J. L. Legoux, T. Aparicio, R. Guimbaud, O. Bouché, F. Ricard e P. Rougier. "P.232 Pratique de la cancérologie digestive par les hépato-gastroentérologues : évolutions de 2000 à 2008 au travers des enquêtes nationales FSMAD-FFCD". Gastroentérologie Clinique et Biologique 33, n. 3 (marzo 2009): A164. http://dx.doi.org/10.1016/s0399-8320(09)72923-9.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Crespel, Céline, Cloé Brami, Paul de Boissieu, Camille Mazza, Kevin Chauvet, Amélie Lemoine, Benoit Gavlak et al. "Évaluation de la faisabilité d’un programme d’activité physique adaptée en hôpital de jour de cancérologie digestive : à partir du point de vue des patients". Bulletin du Cancer 105, n. 3 (marzo 2018): 228–33. http://dx.doi.org/10.1016/j.bulcan.2017.11.011.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

49

Lieu, Christopher H., Lindsay A. Renfro, Aimery de Gramont, Jeffrey P. Meyers, Timothy S. Maughan, Matthew T. Seymour, Leonard Saltz et al. "Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program". Journal of Clinical Oncology 32, n. 27 (20 settembre 2014): 2975–82. http://dx.doi.org/10.1200/jco.2013.54.9329.

Testo completo

Abstract (sommario):

Purpose This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). Patients and Methods A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age, sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study. Results Of total patients, 3,051 (15%) were age ≤ 50 years. Age was prognostic for both OS (P < .001) and PFS (P < .001), with U-shaped risk (ie, highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted for PS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status. Conclusion Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Boige, V., J. L. Raoul, J. P. Pignon, O. Bouche, E. Boucher, J. F. Blanc, J. F. Seitz, L. Bedenne, N. Dupouy e M. Ducreux. "Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003–03 trial)". Journal of Clinical Oncology 23, n. 16_suppl (giugno 2005): 4128. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.4128.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Articoli di riviste sul tema "Cancérologie digestive"

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili